Prognostic Alternative Splicing Signatures in Esophageal Carcinoma
Zodwa Dlamini,Rodney Hull,Sikhumbuzo Z Mbatha,Mohammed Alaouna,You-Lin Qiao,Herbert Yu,Aristotelis Chatziioannou
DOI: https://doi.org/10.2147/CMAR.S305464
2021-06-05
Cancer Management and Research
Abstract:Zodwa Dlamini, 1 Rodney Hull, 1 Sikhumbuzo Z Mbatha, 2 Mohammed Alaouna, 1, 3 You-Lin Qiao, 1, 4 Herbert Yu, 1, 5 Aristotelis Chatziioannou 1, 6, 7 1 SAMRC Precision Prevention & Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, University of Pretoria, Pretoria, South Africa; 2 Department of Surgery, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa; 3 Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 4 Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China; 5 University of Hawaii Cancer Center, Honolulu, HI, USA; 6 Center of Systems Biology, Biomedical Research Foundation Academy of Athens, Athens, Greece; 7 e-NIOS Applications PC, Kallithea, Athens, 17676, Greece Correspondence: Zodwa Dlamini Pan African Cancer Research Institute (PACRI), University of Pretoria, Pretoria, South Africa Tel +27 761474878 Email Alternative splicing (AS) is a method of increasing the number of proteins that the genome is capable of coding for, by altering the pre-mRNA during its maturation. This process provides the ability of a broad range of proteins to arise from a single gene. AS events are known to occur in up to 94% of human genes. Cumulative data have shown that aberrant AS functionality is a major factor in human diseases. This review focuses on the contribution made by aberrant AS functionality in the development and progression of esophageal cancer. The changes in the pattern of expression of alternately spliced isoforms in esophageal cancer can be used as diagnostic or prognostic biomarkers. Additionally, these can be used as targets for the development of new treatments for esophageal cancer. Keywords: esophageal squamous cell carcinoma, adenocarcinoma, splice variants, cell surface receptors, therapeutic targets, biomarkers Esophageal carcinoma is the ninth most prevalent disease reported in 2017, with about 16,940 newly diagnosed cases and an estimated 15,690 fatalities, making it the sixth leading cause of cancer death worldwide. 1 , 2 The most frequent forms of esophageal cancer can be classified into two major histological subtypes. The most widespread in North and Western Europe, North America and Oceania is esophageal adenocarcinoma. In South and Central Asia, including China, the most widespread form is esophageal squamous cell carcinoma (ESCC). 3 , 4 With numerous advancements in screening and multidisciplinary therapy, the average survival rate for 5 years for esophageal cancer varies between 40 and 59%. 5 This high incidence rate and low level of accurate prediction combined with difficulties in diagnosis make markers for cancer of the esophagus a prime area for innovative scientific research. These biomarkers would assist in the early diagnosis and determine the correct treatment for each specific patient. 6 , 7 Alternative splicing (AS) is one of the most important post-transcriptional regulatory pathways 8 and plays an essential role to increase protein complexity. 9 AS is found to occur in up to 94% of human genes. 10 A particular pre-RNA is spliced to give rise to distinct isoforms that are found to have unique expression patterns in multiple tissues and stages of development. 11 Dysregulation of AS may therefore affect important biological processes and, consequently, disease-related pathophysiology. 12 Common splicing disorders have become more and more apparent and therefore could represent appealing molecular markers of tumorigenesis. 13 Invasion and metastasis, apoptosis, hypoxia, alterations in metabolism, angiogenesis, and the escape from immunity take place in a number of oncogenic processes. 14 , 15 Moreover, changes in the expression of several critical splice factors can lead to many changes in the AS of target genes. These target genes act to give cancer cells advantages in growth or survival. 16 Aberrant AS can therefore be regarded as another feature of cancer, and research into systemic AS could provide possible biomarkers for malignancies. 17 </sup -Abstract Truncated-
oncology